INmune Bio to Present Phase III CORDStrom Data for Rare Skin Disorder

INmune Bio announced plans to host a webinar on February 26, 2026, to present new clinical data on its CORDStrom cell therapy candidate for recessive dystrophic epidermolysis bullosa. The MissionEB Phase III trial data to be discussed underscore CORDStrom's positioning as a systemic, disease-modifying alternative to topical standards of care in this rare, severe skin disorder.

The event will feature clinical investigators from the U.K.-based MissionEB study, including lead pediatric RDEB specialist Dr. Anna Martinez and INmune Bio co-founder and chief scientific officer Prof. Mark Lowdell. They are expected to detail outcomes such as improvements in EBDASI skin scores, pediatric weight gain, reductions in pain and itch, and enhanced quality-of-life measures, highlighting potential implications for treatment paradigms and patient management if the therapy ultimately proves successful.

INmune Bio Inc. is a NASDAQ-listed, clinical-stage biotechnology company focused on developing therapies that target the innate immune system to treat inflammatory, autoimmune and cancer indications. Its product platforms include CORDStrom, a pooled allogeneic umbilical cord-derived mesenchymal stromal cell therapy, XPro for selectively neutralizing soluble TNF, and INKmune, a cell-based medicine aimed at enhancing natural killer cell activity in oncology.

The company leverages proprietary screening, pooling and expansion technologies to manufacture off-the-shelf, cGMP-produced cellular medicines designed for consistency, scalability and cost efficiency. Its CORDStrom platform, initially developed as a disease-agnostic cell therapy, can be tuned for indication-specific effector functions such as anti-inflammatory, immunomodulatory and wound-healing properties, with recent randomized trial work completed in recessive dystrophic epidermolysis bullosa.